ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

PIK3CA

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha · also PI3K · Phosphatidylinositol 3-kinase family

14 programs in company-led studies act on PIK3CA, from 14 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
AlpelisibruleNovartisinhibitorphase 43711 running–ChEMBL
inavolisibruleHoffmann-La Rocheinhibitorphase 32017 running–ChEMBL
tersolisibEli Lillyinhibitorphase 3104 running–a judged reading
gedatolisibrulePfizerinhibitorphase 393 runningMTOR, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5ChEMBL
PI3K-alpha Inhibitor JS105ruleRisen (Suzhou) Pharma Techinhibitorphase 311 running–NCIt
serabelisibruleTakedainhibitorphase 2112 running–ChEMBL
risovalisibruleHaihe Biopharmainhibitorphase 242 running–NCIt
zovegalisibruleRelay Therapeuticsinhibitorphase 222 running–NCIt
paxalisibruleKazia Therapeuticsinhibitorphase 241 runningPIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5ChEMBL
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulePikavation Therapeuticsinhibitorphase 211 running–NCIt
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleEnsem Therapeuticsinhibitorphase 211 running–NCIt
Mutant-selective PI3K-alpha Inhibitor RGT-490ruleRegor Pharmaceuticalsinhibitorphase 111 running–NCIt
PI3Ka H1047R Mutant Selective Inhibitor CGT6297ruleCogent Biosciencesinhibitorphase 111 running–NCIt
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerinhibitorphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.